|
Dosing and Compliance Considerations for Growth Factors and the Role of
the Advance Practice Nurse
Release
Date: March
8, 2007
Expiration Date: March 7, 2008
Target
Audience
Oncology Nurse Practitioners and Clinical Nurse Specialists who treat
patients with cancer.
Statement
of Need
Advanced Nurse Specialists who care for patients with cancer need
the most current information on cancer care. This activity will help the
practitioner in understanding the indications and dosing of myeloid growth
factors in the treatment of their patients.
Objectives
Upon completion of this activity, participants should be able to improve
their patient care by being able to:
- Discuss
the various growth factors and the dosing regimens associated with them
to choose the best treatment plan for your patient
- Recognize
dosing and compliance considerations that should be evaluated when determining
the proper course of treatment
- Assess
the role of Q3wk dosing in clinical practice
Faculty
Accreditation
Eastern Kentucky University, the Division of Continuing Education
and Development, is accredited as a provider of continuing nursing education
by the American Nurses Credentialing Center's Commission on Accreditation.
 |
Eastern
Kentucky University, the Division of Continuing Education and Development,
designates this educational activity for 1.0 contact hour. This
activity will provide 1.0 contact hour of nursing credit. Licensees
are required to retain certificates of completion for a period of
five (5) years following the end of their licensure period and submit
certificate to the Board of Nursing only upon request.
|
Instructions
To receive credit for this activity, you must:
- Review
the full content of the activity and reflect on its teaching.
- Successfully
complete the post-test with a minimum grade of 70% or higher.
- You will
have two (2) opportunities to successfully complete the activity.
Your statement
of credit will be issued immediately upon successful completion and submission
of the posttest and evaluation.
Fee
There is no fee for this activity.
Disclosure
Declaration
It is the policy of Creative Educational Concepts, Inc. for individuals
who are in a position to control the content of an educational activity
to disclose to the learners all relevant financial relationships that they
have with any commercial interest(s) that provide products or services that
may be relevant to the content of this continuing medical education activity.
Creative
Educational Concepts, Inc. has no relevant financial relationship with
any commercial interests related directly or indirectly to the content
of this educational activity.
Ralph
V. Boccia, MD, FACP has disclosed that he is a consultant for MedImmune
Inc. and Valeant Pharmaceuticals International. He has received grant/research
support from Amgen Inc., Telik, Inc., Bristol-Myers Squibb Company, Attenuon
LLC, Celgene Corporation, GlaskoSmithKline, Kendle International Inc.,
and MedImmune Inc. He is also on the speakers' bureau for MedImmune Inc.,
MGI PHARMA, Pharmion Corporation, Amgen Inc., and Celgene Corporation.
Diane
Gardner, CRNP has disclosed that she has no actual or potential conflicts
of interest in relation to this activity.
It is the
policy of the accreditors to ensure independence, balance, objectivity,
scientific rigor, and integrity in all of their continuing medical education
activities.
Unlabeled
Use Disclosure
The author and sponsor of this continuing medical education activity have
made all reasonable efforts to ensure that information contained herein
is accurate in accordance with the latest available scientific knowledge
at the time of accreditation of this continuing education activity. Information
regarding drugs (e.g. their administration, dosages, contraindications,
adverse reactions, interactions, special warning, precautions) and drug
delivery systems is subject to change; however, and the reader is advised
to check the manufacturer's package insert for information concerning
recommended dosage and potential problems or cautions prior to dispensing
or administering the drug or using the drug delivery system.
The faculty
has indicated that there will be discussion of unlabeled/unapproved use
of products during the presentation.
Commercial
Support
This activity is supported by an educational grant from Amgen Inc.
Software
Requirements
Continue
|
